Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Digestive Diseases and Sciences
Published in: Digestive Diseases and Sciences 7/2015

01-07-2015 | Review

Gastrointestinal Manifestations of Cystic Fibrosis

Authors: Thomas Kelly, James Buxbaum

Published in: Digestive Diseases and Sciences | Issue 7/2015

Login to get access

Abstract

Gastrointestinal symptoms of cystic fibrosis are the most important non-pulmonary manifestations of this genetic illness. Pancreatic manifestations include acute and chronic pancreatitis as well as pancreas insufficiency resulting in malnutrition. Complications in the gastrointestinal lumen are diverse and include distal intestinal obstruction syndrome (DIOS), meconium ileus, intussusception, and constipation; biliary tract complications include focal biliary cirrhosis and cholangiectasis. The common pathophysiology is the inspissation of secretions in the hollow structures of the gastrointestinal tract. Improved survival of CF patients mandates that the adult gastroenterologist be aware of the presentation and treatment of pancreatic, luminal, and hepatobiliary CF complications.
Literature
1.
Gabriel SE, Brigman KN, Koller BH, et al. Cystic fibrosis heterozygote resistance to cholera toxin in the cystic fibrosis mouse model. Science. 1994;266:107–109.PubMedCrossRef
2.
3.
4.
5.
Blackman SM, Deering-Brose R, McWilliams R, et al. Relative contribution of genetic and nongenetic modifiers to intestinal obstruction in cystic fibrosis. Gastroenterology. 2006;131:1030–1039.PubMedCentralPubMedCrossRef
6.
Kopelman H, Durie P, Gaskin K, et al. Pancreatic fluid secretion and protein hyperconcentration in cystic fibrosis. N Engl J Med. 1985;312:329–334.PubMedCrossRef
7.
Shwachman H, Lebenthal E, Khaw KT. Recurrent acute pancreatitis in patients with cystic fibrosis with normal pancreatic enzymes. Pediatrics. 1975;55:86–95.PubMed
8.
De Boeck K, Weren M, Proesmans M, et al. Pancreatitis among patients with cystic fibrosis: correlation with pancreatic status and genotype. Pediatrics. 2005;115:e463–e469.PubMedCrossRef
9.
King LJ, Scurr ED, Murugan N, et al. Hepatobiliary and pancreatic manifestations of cystic fibrosis: MR imaging appearances. Radiographics. 2000;20:767–777.PubMedCrossRef
10.
Sharer N, Schwarz M, Malone G, et al. Mutations of the cystic fibrosis gene in patients with chronic pancreatitis. N Engl J Med. 1998;339:645–652.PubMedCrossRef
11.
Waters DL, Dorney SF, Gaskin KJ, et al. Pancreatic function in infants identified as having cystic fibrosis in a neonatal screening program. N Engl J Med. 1990;322:303–308.PubMedCrossRef
12.
Proesmans M, De Boeck K. Omeprazole, a proton pump inhibitor, improves residual steatorrhoea in cystic fibrosis patients treated with high dose pancreatic enzymes. Eur J Pediatr. 2003;162:760–763.PubMedCrossRef
13.
Dodge JA, Turck D. Cystic fibrosis: nutritional consequences and management. Best Pract Res Clin Gastroenterol. 2006;20:531–546.PubMedCrossRef
14.
Agrons GA, Corse WR, Markowitz RI, et al. Gastrointestinal manifestations of cystic fibrosis: radiologic-pathologic correlation. Radiographics. 1996;16:871–893.PubMedCrossRef
15.
Liong SY, Awad D, Jones AM, et al. The adult cystic fibrosis patient with abdominal pain: what the radiologist needs to know. Clin Radiol. 2011;66:132–139.PubMedCrossRef
16.
Chaudry G, Navarro OM, Levine DS, et al. Abdominal manifestations of cystic fibrosis in children. Pediatr Radiol. 2006;36:233–240.PubMedCrossRef
17.
Andersen D. Cystic fibrosis of the pancreas and its relation to celiac disease: a clinical and pathologic study. Am J Dis Chil. 1938;56:344–399.CrossRef
18.
19.
Mousa HM, Woodley FW. Gastroesophageal reflux in cystic fibrosis: current understandings of mechanisms and management. Curr Gastroenterol Rep. 2012;14:226–235.PubMedCrossRef
20.
21.
Orenstein SR, Orenstein DM. Gastroesophageal reflux and respiratory disease in children. J Pediatr. 1988;112:847–858.PubMedCrossRef
22.
Eggermont E, Deboeck K. Small-intestinal abnormalities in cystic fibrosis patients. Eur J Pediatr. 1991;150:824–828.PubMedCrossRef
23.
Constantine S, Au VW, Slavotinek JP. Abdominal manifestations of cystic fibrosis in adults: a review. Australas Radiol. 2004;48:450–458.PubMedCrossRef
24.
Grossman H, Berdon WE, Baker DH. Gastrointestinal findings in cystic fibrosis. Am J Roentgenol Radium Ther Nucl Med. 1966;97:227–238.PubMedCrossRef
25.
Abramson SJ, Baker DH, Amodio JB, et al. Gastrointestinal manifestations of cystic fibrosis. Semin Roentgenol. 1987;22:97–113.PubMedCrossRef
26.
Robertson MB, Choe KA, Joseph PM. Review of the abdominal manifestations of cystic fibrosis in the adult patient. Radiographics. 2006;26:679–690.PubMedCrossRef
27.
Phelan MS, Fine DR, Zentlermunro PL, et al. Radiographic abnormalities of the duodenum in cystic fibrosis. Clin Radiol. 1983;34:573–577.PubMedCrossRef
28.
29.
30.
Gorter RR, Karimi A, Sleeboom C, et al. Clinical and genetic characteristics of meconium ileus in newborns with and without cystic fibrosis. J Pediatr Gastroenterol Nutr. 2010;50:569–572.PubMed
31.
32.
Wyllie R. Gastrointestinal manifestations of cystic fibrosis. Clin Pediatr. 1999;38:735–738.CrossRef
33.
Casaccia G, Trucchi A, Nahom A, et al. The impact of cystic fibrosis on neonatal intestinal obstruction: the need for prenatal/neonatal screening. Pediatr Surg Int. 2003;19:75–78.PubMed
34.
Lang I, Daneman A, Cutz E, et al. Abdominal calcification in cystic fibrosis with meconium ileus: radiologic-pathologic correlation. Pediatr Radiol. 1997;27:523–527.PubMedCrossRef
35.
Delpin CA, Czyrko C, Ziegler MM, et al. Management and survival of meconium ileus—A 30-year review. Ann Surg. 1992;215:179–185.CrossRef
36.
Colombo C, Ellemunter H, Houwen R, et al. Guidelines for the diagnosis and management of distal intestinal obstruction syndrome in cystic fibrosis patients. J Cyst Fibros. 2011;10:S24–S28.PubMedCrossRef
37.
Dray X, Bienvenu T, Desmazes-Dufeu N, et al. Distal intestinal obstruction syndrome in adults with cystic fibrosis. Clin Gastroenterol Hepatol. 2004;2:498–503.PubMedCrossRef
38.
Houwen RH, van der Doef HP, Sermet I, et al. Defining DIOS and constipation in cystic fibrosis with a multicentre study on the incidence, characteristics, and treatment of DIOS. J Pediatr Gastroenterol Nutr. 2010;50:38–42.PubMedCrossRef
39.
40.
van der Doef HP, Kokke FT, van der Ent CK, et al. Intestinal obstruction syndromes in cystic fibrosis: meconium ileus, distal. Curr Gastroenterol Rep. 2011;13:265–270.PubMedCentralPubMedCrossRef
41.
Stern RC, Izant RJ, Boat TF, et al. Treatment and prognosis of rectal prolapse in cystic-fibrosis. Gastroenterology. 1982;82:707–710.PubMed
42.
Siafakas C, Vottler TP, Andersen JM. Rectal prolapse in pediatrics. Clin Pediatr. 1999;38:63–72.CrossRef
43.
Nash EF, Stephenson A, Helm EJ, et al. Intussusception in adults with cystic fibrosis: a case series with review of the literature. Dig Dis Sci. 2011;56:3695–3700.PubMedCrossRef
44.
Munck A, Belarbi N, de Lagausie P, et al. Ultrasonography detects appendicular mucocele in cystic fibrosis patients suffering recurrent abdominal pain. Pediatrics. 2000;105:921.PubMedCrossRef
45.
Coughlin JP, Gauderer MWL, Stern RC, et al. The spectrum of appendiceal disease in cystic fibrosis. J Pediatr Surg. 1990;25:835–839.PubMedCrossRef
46.
Lardenoye SW, Puylaert JB, Smit MJ, et al. Appendix in children with cystic fibrosis: US features. Radiology. 2004;232:187–189.PubMedCrossRef
47.
Chaun H. Colonic disorders in adult cystic fibrosis. Can J Gastroenterol. 2001;15:586–590.PubMed
48.
Smyth RL, Vanvelzen D, Smyth AR, et al. Strictures of ascending colon in cystic fibrosis and high-strength pancreatic-enzymes. Lancet. 1994;343:85–86.PubMedCrossRef
49.
Smyth RL, Ashby D, Ohea U, et al. Fibrosing colonopathy in cystic fibrosis—results of a case-control study. Lancet. 1995;346:1247–1251.PubMedCrossRef
50.
Moss RL, Musemeche CA, Feddersen RM. Progressive pan-colonic fibrosis secondary to oral administration of pancreatic enzymes. Pediatr Surg Int. 1998;13:168–170.PubMedCrossRef
51.
Schneider ARJ, Klueber S, Posselt HG, et al. Application of the glucose hydrogen breath test for the detection of bacterial overgrowth in patients with cystic fibrosis–a reliable method? Dig Dis Sci. 2009;54:1730–1735.PubMedCrossRef
52.
Neglia JP, FitzSimmons SC, Maisonneuve P, et al. The risk of cancer among patients with cystic fibrosis. Cystic fibrosis and cancer study group. N Engl J Med. 1995;332:494–499.PubMedCrossRef
53.
Meyer KC, Francois ML, Thomas HK, et al. Colon cancer in lung transplant recipients with CF: increased risk and results of screening. J Cyst Fibros. 2011;10:366–369.PubMedCrossRef
54.
Feranchak AP. Hepatobiliary complications of cystic fibrosis. Curr Gastroenterol Rep. 2004;6:231–239.PubMedCrossRef
55.
Sokol RJ, Durie PR. Cystic Fibrosis Fdn Hepatobiliary Dis C. Recommendations for management of liver and biliary tract disease in cystic fibrosis. J Pediatr Gastroenterol Nutr. 1999;28:S1–S13.PubMedCrossRef
56.
57.
Cohn JA, Strong TV, Picciotto MR, et al. Localization of the cystic fibrosis transmembrane conductance regulator in human bile duct epithelial cells. Gastroenterology. 1993;105:1857–1864.PubMed
58.
Kochar R, Fallon MB. Pulmonary diseases and the liver. Clin Liver Dis. 2011;15:21.
59.
Herrmann U, Dockter G, Lammert F. Cystic fibrosis-associated liver disease. Best Pract Res Clin Gastroenterol. 2010;24:585–592.PubMedCrossRef
60.
Lewindon PJ, Pereira TN, Hoskins AC, et al. The role of hepatic stellate cells and transforming growth factor-beta(1) in cystic fibrosis liver disease. Am J Pathol. 2002;160:1705–1715.PubMedCentralPubMedCrossRef
61.
Lindblad A, Glaumann H, Strandvik B. Natural history of liver disease in cystic fibrosis. Hepatology. 1999;30:1151–1158.PubMedCrossRef
62.
Colombo C, Battezzati PM, Crosignani A, et al. Liver disease in cystic fibrosis: a prospective study on incidence, risk factors, and outcome. Hepatology. 2002;36:1374–1382.PubMedCrossRef
63.
Bartlett JR, Friedman KJ, Ling SC, et al. Genetic modifiers of liver disease in cystic fibrosis. J Am Med Assoc. 2009;302:1076–1083.CrossRef
64.
Lindblad A, Glaumann H, Strandvik B. A two-year prospective study of the effect of ursodeoxycholic acid on urinary bile acid excretion and liver morphology in cystic fibrosis-associated liver disease. Hepatology. 1998;27:166–174.PubMedCrossRef
65.
Colombo C, Crosignani A, Assaisso M, et al. Ursodeoxycholic acid therapy in cystic fibrosis-associated liver disease: a dose-response study. Hepatology. 1992;16:924–930.PubMedCrossRef
66.
Colombo C, Battezzati PM, Podda M, et al. Ursodeoxycholic acid for liver disease associated with cystic fibrosis: a double-mind multicenter trial. Hepatology. 1996;23:1484–1490.PubMedCrossRef
67.
Cheng K, Ashby D, Smyth RL. Ursodeoxycholic acid for cystic fibrosis-related liver disease. Cochrane Database Syst Rev. 2012;10:CD000222.
68.
Imam MH, Sinakos E, Gossard AA, et al. High-dose ursodeoxycholic acid increases risk of adverse outcomes in patients with early stage primary sclerosing cholangitis. Aliment Pharmacol Ther. 2011;34:1185–1192.PubMedCentralPubMedCrossRef
69.
Lindor KD, Kowdley KV, Luketic VA, et al. High-dose ursodeoxycholic acid for the treatment of primary sclerosing cholangitis. Hepatology. 2009;50:808–814.PubMedCentralPubMedCrossRef
70.
Lu BR, Esquivel CO. A review of abdominal organ transplantation in cystic fibrosis. Pediatr Transpl. 2010;14:954–960.CrossRef
71.
Molmenti EP, Squires RH, Nagata D, et al. Liver transplantation for cholestasis associated with cystic fibrosis in the pediatric population. Pediatr Transpl. 2003;7:93–97.CrossRef
72.
Enriquez G, Lucaya J, Allende E, et al. Intrahepatic biliary stone in children. Pediatr Radiol. 1992;22:283–286.PubMedCrossRef
73.
Gaskin KJ, Waters DLM, Howmangiles R, et al. Liver disease and common-bile-duct stenosis in cystic fibrosis. N Engl J Med. 1988;318:340–346.PubMedCrossRef
74.
Perdue DG, Cass OW, Milla C, et al. Hepatolithiasis and Cholangiocarcinoma in cystic fibrosis: a case series and review of the literature. Dig Dis Sci. 2007;52:2638–2642.PubMedCrossRef
75.
Bass S, Connon JJ, Ho CS. Biliary tree in cystic fibrosis: biliary tract abnormalities in cystic fibrosis demonstrated by endoscopic retrograde cholangiography. Gastroenterology. 1983;84:1592–1596.PubMed
76.
Baldwin TL, Schutz SM, Owens G, et al. Successful endoscopic therapy of cholangitis associated with intrahepatic cholangiectasis in adult cystic fibrosis. Gastrointest Endosc. 1999;49:249–251.PubMedCrossRef
77.
Lo CM, Fan ST, Wong J. The changing epidemiology of recurrent pyogenic cholangitis. Hong Kong Med J. 1997;3:302–304.PubMed
78.
79.
Wasmuth HE, Keppeler H, Herrmann U, et al. Coinheritance of Gilbert syndrome-associated UGT1A1 mutation increases gallstone risk in cystic fibrosis. Hepatology. 2006;43:738–741.PubMedCrossRef
80.
Karlas T, Neuschulz M, Oltmanns A, et al. Non-invasive evaluation of cystic fibrosis related liver disease in adults with ARFI, transient elastography and different fibrosis scores. Plos One. 2012;7:8.CrossRef
81.
Treem WR, Stanley CA. Massive hepatomegaly, steatosis, and secondary plasma carnitine deficiency in an infant with cystic fibrosis. Pediatrics. 1989;83:993–997.PubMed
82.
Aldamiz-Echevarria L, Prieto J, Andrade F, et al. Persistence of essential fatty acid deficiency in cystic fibrosis despite nutritional therapy. Pediatr Res. 2009;66:585–589.PubMedCrossRef
83.
Freedman SD, Shea JC, Blanco PG, et al. Fatty acids in cystic fibrosis. Curr Opin Pulm Med. 2000;6:530–532.PubMedCrossRef
84.
Colombo C, Bertolini E, Assaisso ML, et al. Failure of ursodeoxycholic acid to dissolve radiolucent gallstones in patients with cystic fibrosis. Acta Paediatr. 1993;82:562–565.PubMedCrossRef
85.
Angelico M, Gandin C, Canuzzi P, et al. Gallstones in cystic fibrosis: a critical reappraisal. Hepatology. 1991;14:768–775.PubMedCrossRef
86.
Roy CC, Weber AM, Morin CL, et al. Abnormal biliary lipid composition in cystic fibrosis: effect of pancreatic enzymes. N Engl J Med. 1977;297:1301–1305.PubMedCrossRef
Metadata
Title
Gastrointestinal Manifestations of Cystic Fibrosis
Authors
Thomas Kelly
James Buxbaum
Publication date
01-07-2015
Publisher
Springer US
Published in
Digestive Diseases and Sciences / Issue 7/2015
Print ISSN: 0163-2116
Electronic ISSN: 1573-2568
DOI
https://doi.org/10.1007/s10620-015-3546-7

Other articles of this Issue 7/2015

Digestive Diseases and Sciences 7/2015 Go to the issue

Original Article

Anti-miR-362-3p Inhibits Migration and Invasion of Human Gastric Cancer Cells by Its Target CD82

Original Article

Percutaneous Intraluminal Radiofrequency Ablation for Malignant Extrahepatic Biliary Obstruction: A Safe and Feasible Method

Original Article

Combinatorial Intervention with Mesenchymal Stem Cells and Granulocyte Colony-Stimulating Factor in a Rat Model of Ulcerative Colitis

Editorial

Sphincterotomy with Large Balloon to Extract Common Bile Duct Stones: Sometimes It Is Better to Get an “Incomplete”

Original Article

MicroRNA-370 Attenuates Hepatic Fibrogenesis by Targeting Smoothened

Erratum

Erratum to: A Case Series and Literature Review of Merkel Cell Carcinoma Metastasizing to Pancreas
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine
Image Credits